Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Emerald Health Therapeutics Launches Island Mist, One of Canada’s Highest CBD and CBD to THC Ratio Dried Flower Products


Posted on: 18 Sep 17

VICTORIA, British Columbia, Sept. 18, 2017 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (Therapeutics) (TSX-V:EMH) (OCTQX:EMHTF) has released Island Mist, its proprietary high cannabidiol (CBD) and high CBD to THC ratio dried flower product. This Indica-dominant strain, which came out of Emerald’s broad seed bank through extensive screening and characterization, contains 15.9% CBD and just 0.4% THC, a ratio of 40:1. This product can be purchased by holders of a medical license registered with Emerald Health Botanicals (Botanicals), Therapeutics’ wholly owned subsidiary and a Licensed Producer under Access to Cannabis for Medical Purposes Regulations (ACMPR).

Botanicals currently sells a line of six dried flower products, including four strains with THC levels ranging from 16.3% to 21.5%; a high CBD strain; and a strain containing both THC and CBD.

Botanicals now offers eight oils with varying levels of THC, THCA, CBD, and THC to CBD ratios. This product line includes the company’s recently launched CBD-25 and CBD-50 medical cannabis oils containing approximately 25 milligrams and 50 mg of CBD per milliliter. Management believes CBD-50 contains the highest amount of CBD per milliliter on the ACMPR market today. CBD-50 provides a unique option to doctors and patients seeking high CBD potency with minimal THC.

"Island Mist offers patients who prefer dried flower with significant CBD and minute amounts of THC and thus little to no psychoactive effects," said Dr. Bin Huang, President and CEO of Emerald. "We have built a balanced product line that we will add to with our continuing pursuit of distinct products to meet different needs and expectations in the ACMPR marketplace and the anticipated legal Canadian recreational market in 2018.”

Join us on our journey of making lives better through cannabis science.

About Emerald Health Therapeutics Inc.

Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) operates primarily through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary of the Company and a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations. Botanicals is authorized to produce and sell both dried medical cannabis flower and medical cannabis oil in Canada. Botanicals currently operates an indoor facility in Victoria, BC, and is progressing on expansion plans for a 32-acre property in Metro Vancouver and a joint venture with Village Farms utilizing a 25 acre existing greenhouse complex in Delta, BC. Botanicals is one of Canada's most medically focused licensed producers, with a team highly experienced in life sciences product development and large-scale agribusiness. Its vision is to be a leading provider of cannabis products through its production capabilities, proprietary genetics, value-added products and branding, and superb customer experience. Emerald Health Therapeutics is part of the Emerald Health group, which comprises multiple companies advancing diverse botanical, nutraceutical and pharmaceutical products that may provide wellness and medical benefits by interacting with the body’s endocannabinoid system.

For investor and media contacts:

invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

Certain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws.  All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking statements".

We caution you that such "forward-looking statements" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.

Forward-looking statements include, but are not limited to, statements with respect to legalization of non-therapeutic cannabis sales in Canada; participation in the legalized non-therapeutic cannabis industry; growth in the extract-based market; increased production of cannabis; commercial operations; construction or conversion of production facilities; applications for licensing; obtaining such licenses; commencement of production of cannabis at the Company’s facilities; estimates of production capacity at such facilities; contributions of cash to the JV; international opportunities for the Company; commencement of clinical trials; the Company becoming a leading Canadian supplier of cannabis products; expected timing of any of the above matters; and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.

Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, failure of the federal government to approve legislation legalizing sales of non-therapeutic adult-use cannabis; failure to obtain Health Canada and other regulatory approvals; failure to obtain necessary financing; results of production and sale activities; the Company's historical experience with medical marijuana operations; results of scientific research; uninsured risks; regulatory changes; difficulties in construction or in obtaining qualified contractors to complete construction or conversion of facilities; availability of production facilities; timeliness of government approvals and the granting of permits and licenses; changes in prices and costs; actual operating and financial performance of facilities; equipment and processes relative to specifications and expectations; as well as the other risk factors set out in the Company’s annual information form and other filing with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.

GlobeNewswire
globenewswire.com

Last updated on: 18/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.